ENEXIS has made a strategic investment in Demecan, a leading German producer and distributor of medical cannabis, to capitalize on the growing market opportunities in the healthcare sector.
Target Company Overview
Demecan is a prominent German firm specializing in the production and distribution of medical cannabis. With a strong commitment to quality and compliance, Demecan aims to facilitate access to medical cannabis for patients across Germany. The company is recognized for its advanced cultivation techniques and its dedication to ensuring that patients receive safe and effective products.
The organization holds a significant market position within the rapidly evolving medical cannabis sector in Germany. Focused on innovation and sustainable practices, Demecan is set to expand its operational capabilities and market reach to meet the growing demand for medical cannabis.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Germany
The medical cannabis industry in Germany has witnessed substantial growth following the legalization of medical cannabis in 2017. This pivotal change in legislation has led to an increasing acceptance of cannabis as a legitimate
Similar Deals
Springboard Health Angels, Pluton Asset Holding AG, Sintra Ventures, Technologiegründerfonds Sachsen, i&i Bio, HIL-INVENT, Brandenburg Kapital → Captain T Cell
2025
Picus Capital, Alven, Heliad, Rubin Ritter, Lars Langusch, Jens Begemann, Debiopharm, Arve Capital, Christoph Haarburger → StratifAI
2025
ENEXIS
invested in
Demecan
in 2022
in a Other VC deal